We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Forge Therapeutics announced the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application directed to compositions of matter and methods of use of certain 'non-hydroxamate' inhibitors of LpxC for the tr